MSB 0.54% 92.0¢ mesoblast limited

Thanks. That is interesting. Expert opinion is needed to...

  1. 1,253 Posts.
    lightbulb Created with Sketch. 1403
    Thanks. That is interesting. Expert opinion is needed to evaluate the results of that study. Are there any studies which report a different result?

    However, even if the theorised cytokine storm is not the usual cause of death and severe disability in Covid-ARDS patients on ventilators that still does not invalidate the observation that Covid-ARDS kills and Rem-L saves lives (if it does) in these patients. Something is doing it and if Rem-L fixes it, so what?

    The FDA might grizzle about being asked to approve a treatment for which the MOA is unclear but they sure would be on the nose if they refused to approve something (Rem-L) that was proven to dramatically save lives in a RCT that they had sanctioned. The US is heading for 400,000 Covid-ARDS fatalities early next year, cytokine storm or not. There is a good chance that Rem-L can make a real difference.

    Elevated cytokines is not a required inclusion criterion for the trial. Changes in inflammatory marker levels are studied for the secondary outcome measures but there is no requirement for any particular result to qualify.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
92.0¢
Change
-0.005(0.54%)
Mkt cap ! $1.050B
Open High Low Value Volume
92.0¢ 92.5¢ 91.5¢ $1.133M 1.233M

Buyers (Bids)

No. Vol. Price($)
13 151980 91.5¢
 

Sellers (Offers)

Price($) Vol. No.
92.0¢ 29989 2
View Market Depth
Last trade - 16.10pm 18/09/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.